Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial

BACKGROUND: Bone metastasis is a hallmark of advanced prostate cancer. The endothelin pathway has a mechanistic role in bone metastases. Atrasentan, an endothelin receptor antagonist, has reported activity in prostate cancer. We assessed the survival impact of atrasentan in castration resistant pros...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Lancet Oncol
Autors principals: Quinn, David I., Tangen, Catherine M., Hussain, Maha, Lara, Primo N., Goldkorn, Amir, Moinpour, Carol M., Garzotto, Mark G., Mack, Philip C., Carducci, Michael A., Monk, J. Paul, Twardowski, Przemyslaw W., Van Veldhuizen, Peter J., Agarwal, Neeraj, Higano, Celestia S., Vogelzang, Nicholas J., Thompson, Ian M.
Format: Artigo
Idioma:Inglês
Publicat: 2013
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4277263/
https://ncbi.nlm.nih.gov/pubmed/23871417
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(13)70294-8
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars